We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Group CBT for Depression and AOD Disorders (BRIGHT2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01154309
Recruitment Status : Completed
First Posted : June 30, 2010
Last Update Posted : November 16, 2011
Behavioral Health Services, Inc.
Information provided by (Responsible Party):

June 29, 2010
June 30, 2010
November 16, 2011
September 2006
September 2009   (Final data collection date for primary outcome measure)
  • Reductions in depressive symptoms as measured by the BDI II [ Time Frame: Post treatment ]
  • Reductions in AOD use [ Time Frame: Post treatment ]
  • Reductions in depressive symptoms as measured by the BDI II [ Time Frame: At immediate post-intervention and 3 month follow-up ]
  • Reductions in AOD use [ Time Frame: Immediate post-intervention and 3 months later ]
Complete list of historical versions of study NCT01154309 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Group CBT for Depression and AOD Disorders
Group Cognitive Behavioral Therapy for Depression and Alcohol and Other Drug Disorders
The investigators will adapt and test an existing treatment (group CBT for depression) for use in outpatient substance use treatment settings as delivered by trained substance use counselors. The investigators expect that treatment will lead to improved depression and substance use outcomes.

Aim 1. To adapt an existing group therapy (CBT for depression), creating a manualized treatment and accompanying implementation measures and tools for use with clients with persistent depressive symptoms and AOD disorders and to obtain preliminary assessments of the treatment from patient and provider perspectives.

Aim 2. To conduct a pilot test of the revised treatment in which we (a) demonstrate that when the therapy is implemented with fidelity, clinically significant reductions in depressive symptoms and AOD use occur; (b) estimate the likely effect size; and (c) investigate the underlying mechanisms of change, including both cognitive-behavioral and group processes and their relationship to depression and AOD treatment outcomes.

Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Depression
  • Substance Use
Behavioral: Group CBT for Depression and AOD Disorders
18 sessions of 2-hour group CBT
  • Experimental: 1
    Clients are invited to attend 18 group CBT sessions
    Intervention: Behavioral: Group CBT for Depression and AOD Disorders
  • No Intervention: 2
    Clients receive usual care
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
September 2009
September 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Enrolled in outpatient substance abuse program
  • BDI II score >13
  • Probable alcohol or substance use problem

Exclusion Criteria:

  • Cognitive impairment (Short Blessed > 10)
  • Probably bipolar or schizophrenic disorder
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
R01DA020159( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Behavioral Health Services, Inc.
Principal Investigator: Katherine E Watkins, MD, MSHS RAND
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP